Staff profile

Dr. Li Jiang is an Associate Professor of Intellectual Property law at Shanghai International College of Intellectual Property, Tongji University, where she teaches patent law, new frontiers of intellectual property law and biotechnological invention intellectual property protection. Prior to joining sicip, she was a lecturer at Kenneth Wang School of Law, Soochow University. She holds a Ph.D. from Bangor University Law School, UK, a LL.M from Shandong University, China and a B.S. in Biotechnology from University of Science and Technology Beijing, China. Her scholarship focuses on the scope of patentability in respect of the application of the moral exclusion to patent application as well as regulation of emerging biotechnology such as stem cell technology and genome editing technology.

She has written one book published in Springer and many articles in scholarly journals such as New Genetic and Society, Science and Engineering Ethic, Biosocieties, Biotechnology Law Report etc. She also has been awarded fund by National Social Science Foundation in China, Ministry of Justice, China Law Society etc., which is related to the ethical, social, and regulatory issues that arise from the uptake of genome editing research and human embryonic stem cell. She is the reviewer for many journals including journal of Law and the Biosciences, Asia Pacific Law Review, Biosocieties, Stem Cell Translational Medicine, Pharmaceutical Patent Analyst etc. She is also a lawyer and patent attorney in China.

Authored book

1. Regulating Human Embryonic Stem Cell in China- A Comparative Study on Human Embryonic Stem Cell’s Patentability and Morality in US and EU, Springer (2016)

Journal Articles

1. Li Jiang, “Regulating gene edited plant: challenges and solutions” (2023) 498 Law Science 125-138. 
2. Li Jiang and Hong Yang, “Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China” (2022) 41 Biotechnology Law Report 186-193. 
3. Li Jiang, “14-Day limit of human embryo research: moral issues in the patent law in China” (2021) 40 Biotechnology Law Report 393-408. 
4. Li Jiang，“Commercialization of the gene-edited crop and morality: challenges from liberal patent law and strict GMO law in the EU” (2020) 39 New Genetic and Society 191-218.
5. Li Jiang,“Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent” (2019) 25 Science and Engineering Ethic 791-811. 
6. Li Jiang and Rosemann Achim，“Human embryo gene editing in China: the uncertain legal status of the embryo”（2019）14 BioSocieties 46-66. 
7. Li Jiang，“Centralised Intellectual Property Administrative Management Reform in China: Why it is needed and whether it works” (2018) 111 Intellectual Property Forum 19-24
8. Achim Rosemann, Xinqing Zhang and Li Jiang, “Human Germ Line Gene Editing: Why Comparative, 
9. Cross-National Studies of Public Viewpoints are Important” (2017) 5 Anthropology 175-178.
10. Li Jiang and Binghe Dong“Fraudsters Operate and Officialdom Turns a Blind Eye: a Proposal for Controlling Stem Cell Therapy in China” (2016) 19 Medicine, Health Care and Philosophy 403-410.
11.  Li Jiang, “Will Wild East End Scientific Feast-the First Administrative Measure on Clinical Stem Cell Research in China” (2016) 35 Biotechnology Law Report 27-35. 
12.  Li Jiang, “Will Diversity Regulations Disadvantage Human Embryonic Stem Cell Research: a Comparison between EU and US” (2015) 25 Depaul Journal of Art, Technology and Intellectual Property Law 53-90.            Li Jiang, “Between Scylla and Charybdis: Patentability And Morality Related To Human Embryonic Stem Cells”（2015）6 American University Intellectual Property Brief  53-97.
13. Li jiang and Wei Shi, “Space for Flexibility: Lessons from the European Union Harmonization Model in Human Embryonic Stem Cell Regulation” (2014) 97 Intellectual Property Forum 63-68.

Book Chapters

1.  Li Jiang, “Biotechnology Directive: A Major Step in Biotechnology Patent Law in Europe” in  Keswani, C. (eds) Bioeconomy for Sustainable Development. Springer, Singapore, (2020)
2. Li Jiang, “The Regulation of Genome Editing Technologies and New Methods of Germline Interventions in China” in Jochen Taupitz and Deuring Silvia (ed.) Rechtliche Aspekte der Genom-Editierung an der menschlichen Keimbahn, Springer (2019) 
3. Li Jiang,“The Regulation of Clinical Stem Cell in China” in Phuc Pham & Achim Rosemann (ed.), Stem Cells in Clinical Application: Safety, Ethics and Regulation, Springer (2017)
4. Li Jiang, “Patentability of Human Embryo Stem Cell: A Comparative Analyse of Case WARF in United States and Europe” in H. B. Singh, A. Jha and C. Keswani (ed.), Intellectual Property Issues in Biotechnology, CABI (2016)